Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL1904B CAR-T for Relapsed/Refractory NHL
NCT04447547Unknown
- Sponsor
- Senlang Bio
- Start
- Jun 2020
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Open-label, single-arm trial of sl1904b in non-Hodgkin lymphoma (NHL), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Overall Remission Rate at 3 months. Status: unknown.
02
Drugs
sl1904b
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04447547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447547.